News
The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...
Speaking at BIO 2025, Makary bemoaned what he called “unnecessary steps” and “avoidable delays” in the U.S. regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback